{"id":"deferiprone-dose-level-3","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Gastrointestinal disturbances"},{"rate":"5-10%","effect":"Hepatotoxicity"},{"rate":"5-10%","effect":"Bone marrow suppression"}]},"_chembl":{"chemblId":"CHEMBL70927","moleculeType":"Small molecule","molecularWeight":"139.15"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Deferiprone is an iron chelator that binds to iron ions, forming a stable complex that is excreted from the body. This mechanism helps to reduce the accumulation of iron in tissues, particularly in the liver and heart, which can be beneficial for patients with iron overload conditions.","oneSentence":"Deferiprone chelates iron, reducing its accumulation in tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:10:11.000Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of beta-thalassemia major"},{"name":"Treatment of other iron overload conditions"}]},"trialDetails":[{"nctId":"NCT07292259","phase":"PHASE2","title":"Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia","status":"RECRUITING","sponsor":"Pakistan Blood and Marrow Transplant (PBMT) Group","startDate":"2024-01-01","conditions":"Transfusion Dependent Beta Thalassemia","enrollment":150},{"nctId":"NCT06006091","phase":"NA","title":"The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)","status":"RECRUITING","sponsor":"International Peace Maternity and Child Health Hospital","startDate":"2023-08-01","conditions":"Letrozole, Infertility, Female","enrollment":858},{"nctId":"NCT02041299","phase":"PHASE4","title":"Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias","status":"TERMINATED","sponsor":"ApoPharma","startDate":"2014-04-17","conditions":"Iron Overload, Sickle Cell Disease, Other Anemias","enrollment":230},{"nctId":"NCT02878538","phase":"EARLY_PHASE1","title":"A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2018-01","conditions":"Mild Cognitive Impairment","enrollment":""},{"nctId":"NCT02065492","phase":"PHASE2, PHASE3","title":"Amlodipine for Myocardial Iron in Thalassemia","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2014-02","conditions":"Thalassemia","enrollment":20},{"nctId":"NCT01740713","phase":"PHASE2","title":"Pharmacokinetic Study of Deferiprone in Paediatric Patients","status":"COMPLETED","sponsor":"Consorzio per Valutazioni Biologiche e Farmacologiche","startDate":"2012-12","conditions":"Chronic Iron Overload","enrollment":23},{"nctId":"NCT02173951","phase":"PHASE2, PHASE3","title":"An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2014-07","conditions":"Beta Thalassemia Major","enrollment":64},{"nctId":"NCT01989455","phase":"PHASE1","title":"A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2013-11","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT02191657","phase":"PHASE1","title":"Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2006-11","conditions":"HIV Infection","enrollment":26},{"nctId":"NCT00943748","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2009-10","conditions":"Parkinson's Disease","enrollment":40},{"nctId":"NCT01511848","phase":"PHASE2, PHASE3","title":"Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2012-02","conditions":"Beta-thalassemia Major, Sickle Cell Disease, Iron Hemosiderosis","enrollment":60},{"nctId":"NCT00529152","phase":"PHASE3","title":"Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients","status":"COMPLETED","sponsor":"ApoPharma","startDate":"2007-08","conditions":"Iron Overload","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DFP"],"phase":"phase_2","status":"active","brandName":"Deferiprone, dose level 3","genericName":"Deferiprone, dose level 3","companyName":"Consorzio per Valutazioni Biologiche e Farmacologiche","companyId":"consorzio-per-valutazioni-biologiche-e-farmacologiche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Deferiprone chelates iron, reducing its accumulation in tissues. Used for Treatment of beta-thalassemia major, Treatment of other iron overload conditions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}